Zoetis (NYSE:ZTS) Rating Reiterated by Piper Sandler

Zoetis (NYSE:ZTS)‘s stock had its “overweight” rating restated by investment analysts at Piper Sandler in a research note issued on Tuesday, Benzinga reports. They currently have a $195.00 target price on the stock, down from their previous target price of $220.00. Piper Sandler’s price target indicates a potential upside of 28.34% from the stock’s current price.

ZTS has been the topic of several other reports. StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Stifel Nicolaus lowered their target price on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Barclays increased their target price on shares of Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 14th. Jefferies Financial Group reissued a “buy” rating and set a $230.00 target price on shares of Zoetis in a research report on Tuesday, December 19th. Finally, The Goldman Sachs Group increased their target price on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $221.75.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $151.94 on Tuesday. The company’s fifty day moving average is $177.35 and its two-hundred day moving average is $180.39. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. Zoetis has a 12-month low of $148.48 and a 12-month high of $201.92. The company has a market cap of $69.49 billion, a P/E ratio of 29.97, a price-to-earnings-growth ratio of 2.29 and a beta of 0.85.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The company had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. During the same period last year, the company posted $1.15 earnings per share. The company’s revenue was up 8.5% compared to the same quarter last year. Equities analysts expect that Zoetis will post 5.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $197.74, for a total transaction of $71,779.62. Following the completion of the transaction, the executive vice president now owns 20,417 shares in the company, valued at $4,037,257.58. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.15% of the company’s stock.

Institutional Trading of Zoetis

Several hedge funds have recently modified their holdings of ZTS. Norges Bank acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $745,861,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Zoetis by 31.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after purchasing an additional 3,244,074 shares in the last quarter. Morgan Stanley increased its holdings in shares of Zoetis by 34.6% in the fourth quarter. Morgan Stanley now owns 10,872,704 shares of the company’s stock valued at $1,593,395,000 after purchasing an additional 2,796,694 shares in the last quarter. Moneta Group Investment Advisors LLC increased its holdings in shares of Zoetis by 124,281.9% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 2,332,160 shares of the company’s stock valued at $341,778,000 after purchasing an additional 2,330,285 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in shares of Zoetis by 171.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 3,326,448 shares of the company’s stock valued at $627,335,000 after purchasing an additional 2,102,306 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.